ArticleGlobal health & medicine2026
Artificial intelligence (AI)-assisted full-course case management for primary liver cancer: System design, preliminary implementation, and practical considerations.
Article in Global health & medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary liver cancer presents substantial management challenges across the surgical trajectory, including high recurrence rates, prolonged rehabilitation, and fragmented post-discharge care. This correspondence presents a multidisciplinary physician-nurse co-led, artificial intelligence (AI)-assisted full-course case management model grounded in just-in-time adaptive intervention (JITAI) theory. The model spans four phases-peri-admission, perioperative, post-discharge home-based care, and long-term follow-up-supported by an intelligent platform enabling automated decision triggering, symptom monitoring, tailored health education, and intervention matching. A pilot study with 25 patients was conducted from March to May 2026 at a tertiary cancer hospital in Tianjin, China. Preliminary results revealed improvements in antiviral medication adherence (80-96%), targeted therapy adherence (96-100%), and satisfaction (99.8%), with reductions in missed follow-ups and symptom reporting delays. Multicenter controlled studies need to be conducted to evaluate this model's effectiveness, cost-effectiveness, and long-term sustainability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.